GLAUKOS Q3 2026 earnings

GKOS · 2026-10-28 16:10 AMC ET · 8-K on SEC

Record net sales of $211.0 million (+58% YoY) and raised 2026 guidance to $775M-$785M, with GAAP net income turning positive to $2.0 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$211.0M+58%+13.7%Ex. 99.1, income statement
EPS (GAAP)$0.03+0.31+0.31Ex. 99.1, income statement
EPS (adjusted)$0.47+0.63+0.33Ex. 99.1, income statement
Net income$2.0M$18.2M$2.0MEx. 99.1, income statement
Adj. EBITDA$27.3M$9.3M$19.7MEx. 99.1, income statement
Adj. EBITDA margin12.9%+1.3 pp+5.3 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
U.S. Glaucoma$118.6M+47%56%Record sales
Corneal Health$59.0M+154%28%Record sales
International$33.4M+51%16%Derived

Margins and costs

  • Gross margin 85.2% (prior 78.3%, change +6.9 pp)
  • Operating expenses $179.0M (+58% YoY)
  • One-offs in the quarter Acquired in-process R&D (IPR&D) charge of $1.5M
  • Effective tax rate 14% (prior-year 1.5%, year-to-date 4.2%)
  • Non-GAAP bridge Adds back IPR&D charge, amortization of intangibles, acquisition-related costs, integration costs, restructuring, inventory write-downs, legal costs, and discrete tax adjustments.

KPIs

MetricActualPrior quarterPrior yearChange
Cash & equivalents + short-term investments + restricted cash$339.8M$289.3M$289.3M+$50.5M

Guidance

MetricGuidePrior guideChange
2026 Net sales$775M-$785M$680M-$700M+$75M-$85M
2027 Net sales (preliminary)$1.0B——

What drove it

  • Revenue story U.S. Glaucoma +47% ($118.6M), Corneal Health +154% ($59.0M), and International +51% ($33.4M).
  • EPS story GAAP EPS turned positive to $0.03, driven by net income of $2.0M and lower tax rate.
  • One-off check Acquired in-process R&D (IPR&D) charge of $1.5M included in GAAP loss from operations and adjusted loss from operations.

The good

  • Record net sales of $211.0M (+58% YoY)
  • GAAP net income turned positive to $2.0M
  • Raised 2026 net sales guidance to $775M-$785M

The bad

  • SG&A expenses increased 58% to $130.9M
  • R&D expenses increased 26% to $48.1M

The ugly

  • none

Open questions

  • What specific drivers caused SG&A to increase 58% YoY?
  • What specific drivers caused R&D to increase 26% YoY?
Full release

Earnings: GKOS — filed 2026-10-28

GLAUKOS Corp (GKOS) · Form 8-K, Item 2.02 · Filed · SEC filing

Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs clewis@glaukos.com

Glaukos Announces Third Quarter 2026 Financial Results

Aliso Viejo, CA – October 28, 2026 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:

• Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis.

• U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-over-year.

• Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-over-year.

• Gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026.

• Net income of $2.0 million and non-GAAP net income of $28.5 million in Q3 2026.

• Diluted earnings per share (EPS) of $0.03 and non-GAAP diluted EPS of $0.47 in Q3 2026.

• Cash and cash equivalents, short-term investments, and restricted cash of $339.8 million at the end of Q3 2026, an increase of $50.5 million compared to $289.3 million at the end of Q2 2026.

• Raised 2026 net sales guidance to $775 million to $785 million, compared to $680 million to $700 million previously.

• Introduced preliminary 2027 net sales guidance of $1 billion.

“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and

Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Third Quarter 2026 Financial Results

Net sales in the third quarter of 2026 of $211.0 million increased 58% on a reported and constant currency basis, compared to $133.5 million in the same period in 2025.

Gross margin for the third quarter of 2026 was approximately 85%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the third quarter of 2026 was approximately 88%, compared to approximately 84% in the same period in 2025.

Selling, general and administrative (SG&A) expenses for the third quarter of 2026 increased 58% to $130.9 million, compared to $83.0 million in the same period in 2025. Non-GAAP SG&A expenses for the third quarter of 2026 increased 32% to $109.7 million, compared to $83.2 million in the same period in 2025.

GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2026 increased 26% to $48.1 million, compared to $38.1 million in the same period in 2025.¹

Income from operations in the third quarter of 2026 was $0.8 million, compared to operating loss of $16.4 million in the third quarter of 2025. Non-GAAP income from operations in the third quarter of 2026 was $27.3 million, compared to non-GAAP operating loss of $9.3 million in the third quarter of 2025.

Net income in the third quarter of 2026 was $2.0 million, or $0.03 per diluted share, compared to net loss of $16.2 million, or ($0.28) per diluted share, in the third quarter of 2025. Non-GAAP net income in the third quarter of 2026 was $28.5 million, or $0.47 per diluted share, compared to non-GAAP net loss of $9.2 million, or ($0.16) per diluted share, in the third quarter of 2025.

The company ended the third quarter of 2026 with approximately $339.8 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.

2026 Revenue Guidance

The company expects 2026 net sales to be in the range of $775 million to $785 million based on the latest foreign currency exchange rates.

2027 Preliminary Revenue Guidance

The company expects preliminary 2027 net sales to be $1 billion based on the latest foreign currency exchange rates.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 517868366. A replay of the webcast will be archived on the company’s website following completion of the call.

Quarterly Summary Document

The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.

About Glaukos

Glaukos ( www.glaukos.com... (truncated) commercial launch activities for iDose®

TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,² dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Financial statements

Income Statement

Three Months Ended — (in thousands, except per share amounts)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net sales211,030133,537547,211364,321
Cost of sales31,16428,83198,51980,043
Gross profit179,866104,706448,692284,278
Operating expenses:Selling, general and administrative130,94382,999339,946237,047
Operating expenses:Research and development48,09538,072143,541106,963
Operating expenses:Acquired in-process research and development1,500
Operating expenses:Total operating expenses179,038121,071484,987344,010
Operating expenses:Income (loss) from operations828-16,365-36,295-59,732
Non-operating income (expense):Interest income2,4932,5527,2038,202
Non-operating income (expense):Interest expense-1,087-1,175-3,671-3,489
Non-operating income (expense):Other income (expense), net87-1,009-1,9361,793
Non-operating income (expense):Total non-operating income1,4933681,5966,506
Non-operating income (expense):Income (loss) before taxes2,321-15,997-34,699-53,226
Non-operating income (expense):Income tax provision3032341,443808
Non-operating income (expense):Net income (loss)2,018-16,231-36,142-54,034
Non-operating income (expense):Basic net income (loss) per share0.03-0.28-0.62-0.95
Non-operating income (expense):Diluted net income (loss) per share0.03-0.28-0.62-0.95
Non-operating income (expense):Weighted-average shares outstanding used to compute basic net income (loss) per share59,10557,39858,65157,083
Non-operating income (expense):Weighted-average shares outstanding used to compute diluted net income (loss) per share61,19657,39858,65157,083

Income Statement

(unaudited) (in thousands)

Q3 2026 – GAAPQ3 2026 – AdjustmentsQ3 2026 – Non-GAAPQ3 2025 – GAAPQ3 2025 – AdjustmentsQ3 2025 – Non-GAAP
Cost of sales31,164-5,27425,89028,831-7,31021,521
Gross Margin85.2%2.5%87.7%78.4%5.5%83.9%
Operating expenses:Selling, general and administrative130,943-21,219109,72482,99924383,242
Operating expenses:Income (loss) from operations82826,49327,321-16,3657,067-9,298
Operating expenses:Net income (loss)2,01826,49328,511-16,2317,067-9,164
Operating expenses:Basic net income (loss) per share0.030.450.48-0.280.12-0.16
Operating expenses:Diluted net income (loss) per share0.030.440.47-0.280.12-0.16
Operating expenses:Weighted-average shares outstanding used to compute basic net income (loss) per share59,10559,10557,39857,398
Operating expenses:Weighted-average shares outstanding used to compute diluted net income (loss) per share61,19661,19657,39857,398

Income Statement

Year-to-Date Q3 2026 — (unaudited) (in thousands)

Year-to-Date Q3 2026 – GAAPYear-to-Date Q3 2026 – AdjustmentsYear-to-Date Q3 2026 – Non-GAAPYear-to-Date Q3 2025 – GAAPYear-to-Date Q3 2025 – AdjustmentsYear-to-Date Q3 2025 – Non-GAAP
Cost of sales98,519-19,22279,29780,043-18,59761,446
Gross Margin82.0%3.5%85.5%78.0%5.1%83.1%
Operating expenses:Selling, general and administrative339,946-26,316313,630237,047-52236,995
Operating expenses:(Loss) income from operations-36,29545,5389,243-59,73218,649-41,083
Non-operating income (expense):Interest expense-3,671369-3,302-3,489$--3,489
Non-operating income (expense):Net (loss) income-36,14245,9079,765-54,03418,649-35,385
Non-operating income (expense):Basic net (loss) income per share-0.620.790.17-0.950.33-0.62
Non-operating income (expense):Diluted net (loss) income per share-0.620.780.16-0.950.33-0.62
Non-operating income (expense):Weighted-average shares outstanding used to compute basic net income (loss) per share58,65158,65157,08357,083
Non-operating income (expense):Weighted-average shares outstanding used to compute diluted net income (loss) per share (G)58,65160,59857,08357,083

Income Statement

Three Months Ended — (in thousands, except per share amounts)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net sales211,030133,537547,211364,321
Cost of sales31,16428,83198,51980,043
Gross profit179,866104,706448,692284,278
Operating expenses:Selling, general and administrative130,94382,999339,946237,047
Operating expenses:Research and development48,09538,072143,541106,963
Operating expenses:Acquired in-process research and development1,500
Operating expenses:Total operating expenses179,038121,071484,987344,010
Operating expenses:Income (loss) from operations828-16,365-36,295-59,732
Non-operating income (expense):Interest income2,4932,5527,2038,202
Non-operating income (expense):Interest expense-1,087-1,175-3,671-3,489
Non-operating income (expense):Other income (expense), net87-1,009-1,9361,793
Non-operating income (expense):Total non-operating income1,4933681,5966,506
Non-operating income (expense):Income (loss) before taxes2,321-15,997-34,699-53,226
Non-operating income (expense):Income tax provision3032341,443808
Non-operating income (expense):Net income (loss)2,018-16,231-36,142-54,034

Income Statement

(unaudited) (in thousands)

Q3 2026 – GAAPQ3 2026 – AdjustmentsQ3 2026 – Non-GAAPQ3 2025 – GAAPQ3 2025 – AdjustmentsQ3 2025 – Non-GAAP
Cost of sales31,164-5,27425,89028,831-7,31021,521
Gross Margin85.2%2.5%87.7%78.4%5.5%83.9%
Operating expenses:Selling, general and administrative130,943-21,219109,72482,99924383,242
Operating expenses:Income (loss) from operations82826,49327,321-16,3657,067-9,298
Operating expenses:Net income (loss)2,01826,49328,511-16,2317,067-9,164
Operating expenses:Basic net income (loss) per share0.030.450.48-0.280.12-0.16
Operating expenses:Diluted net income (loss) per share0.030.440.47-0.280.12-0.16
Operating expenses:Weighted-average shares outstanding used to compute basic net income (loss) per share59,10559,10557,39857,398
Operating expenses:Weighted-average shares outstanding used to compute diluted net income (loss) per share61,19661,19657,39857,398

Income Statement

Year-to-Date Q3 2026 — (unaudited) (in thousands)

Year-to-Date Q3 2026 – GAAPYear-to-Date Q3 2026 – AdjustmentsYear-to-Date Q3 2026 – Non-GAAPYear-to-Date Q3 2025 – GAAPYear-to-Date Q3 2025 – AdjustmentsYear-to-Date Q3 2025 – Non-GAAP
Cost of sales98,519-19,22279,29780,043-18,59761,446
Gross Margin82.0%3.5%85.5%78.0%5.1%83.1%
Operating expenses:Selling, general and administrative339,946-26,316313,630237,047-52236,995
Operating expenses:(Loss) income from operations-36,29545,5389,243-59,73218,649-41,083
Non-operating income (expense):Interest expense-3,671369-3,302-3,489$--3,489
Non-operating income (expense):Net (loss) income-36,14245,9079,765-54,03418,649-35,385
Non-operating income (expense):Basic net (loss) income per share-0.620.790.17-0.950.33-0.62
Non-operating income (expense):Diluted net (loss) income per share-0.620.780.16-0.950.33-0.62
Non-operating income (expense):Weighted-average shares outstanding used to compute basic net income (loss) per share58,65158,65157,08357,083
Non-operating income (expense):Weighted-average shares outstanding used to compute diluted net income (loss) per share (G)58,65160,59857,08357,083

Balance Sheet

September 30, — (in thousands, except par values)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assets:Cash and cash equivalents162,32790,813
Current assets:Short-term investments174,372187,947
Current assets:Accounts receivable, net150,004108,608
Current assets:Inventory61,03263,564
Current assets:Prepaid expenses and other current assets31,91524,052
Current assets:Total current assets579,650474,984
Current assets:Restricted cash3,1153,834
Current assets:Property and equipment, net112,068113,253
Current assets:Operating lease right-of-use asset30,79531,527
Current assets:Finance lease right-of-use asset37,59439,404
Current assets:Intangible assets, net121,261141,916
Current assets:Goodwill66,71066,710
Current assets:Deposits and other assets28,33621,859
Current assets:Total assets979,529893,487
Current liabilities:Accounts payable24,40724,624
Current liabilities:Accrued liabilities102,31976,651
Current liabilities:Total current liabilities126,726101,275
Current liabilities:Operating lease liability35,05735,767
Current liabilities:Finance lease liability66,92668,109
Current liabilities:Deferred tax liability, net441441
Current liabilities:Other liabilities33,10531,740
Current liabilities:Total liabilities262,255237,332
Stockholders' equity:Common stock, $0.001 par value; 150,000 shares authorized; 59,196 and 57,539 shares issued and 59,168 and 57,511 shares outstanding at September 30, 2026 and December 31, 2025, respectively5958
Stockholders' equity:Additional paid-in capital1,684,8291,586,056
Stockholders' equity:Accumulated other comprehensive income1,7903,303
Stockholders' equity:Accumulated deficit-969,272-933,130
Stockholders' equity:Less treasury stock (28 shares as of September 30, 2026 and December 31, 2025)-132-132
Stockholders' equity:Total stockholders' equity717,274656,155
Stockholders' equity:Total liabilities and stockholders' equity979,529893,487

Balance Sheet

September 30, — (in thousands, except par values)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assets:Cash and cash equivalents162,32790,813
Current assets:Short-term investments174,372187,947
Current assets:Accounts receivable, net150,004108,608
Current assets:Inventory61,03263,564
Current assets:Prepaid expenses and other current assets31,91524,052
Current assets:Total current assets579,650474,984
Current assets:Restricted cash3,1153,834
Current assets:Property and equipment, net112,068113,253
Current assets:Operating lease right-of-use asset30,79531,527
Current assets:Finance lease right-of-use asset37,59439,404

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and

Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to file on or before November 9, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.³

Statement Regarding Use of Non-GAAP Financial Measures... (truncated)to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.⁴

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · GLAUKOS earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.